Christine N. Spencer

Author

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

C. N. Spencer, Christine N Spencer, Christine N. Spencer, Christine Spencer, Spencer, Christine

241

Publications

11.8K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Parker Institute for Cancer Immunotherapy Memorial Sloan Kettering Cancer Center Baylor College of Medicine Massachusetts General Hospital

About

Christine N. Spencer is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, immunology, and gut microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	5.6K
2	Public Health	3	3	873
3	Health Sciences	2	2	673
4	Allergy	2	2	69
5	Biostatistics	1	1	11

Christine N. Spencer

Publications

10.3K

Citations

H-Index

Page 1

	Year	Citations
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients Vancheswaran Gopalakrishnan, Christine N. Spencer, Luigi Nezi, Science	2017	4.4K
B cells and tertiary lymphoid structures promote immunotherapy response Beth A. Helmink, Sangeetha M. Reddy, Jianjun Gao, Nature Humoral ResponseImmunologyB CellsAutoimmunityHumoral Immunity	2020	2.5K
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response Christine N. Spencer, Jennifer L. McQuade, Vancheswaran Gopalakrishnan, Science NutritionDysbiosisGut BacteriaImmunologyDietary Fibre	2021	804
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma Rodabe N. Amaria, Sangeetha M. Reddy, Hussein A. Tawbi, Nature Medicine MedicineMelanomaImmunologyTumor ImmunityImmune Checkpoint Inhibitor	2018	797
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess, The Lancet Oncology OncologyBody CompositionCancer ManagementMelanomaMetastatic Melanoma	2018	647
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade Miles C. Andrews, Connie P.M. Duong, Vancheswaran Gopalakrishnan, Nature Medicine DysbiosisHealth SciencesMucosal ImmunologyPd-1 BlockadeMedicine	2021	388
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial Rodabe N. Amaria, Peter A. Prieto, Michael T. Tetzlaff, The Lancet Oncology Surgical OncologyMedicineCancer ManagementMelanomaClinical Trials	2018	285
Hallmarks of Resistance to Immune-Checkpoint Inhibitors Maria Karasarides, Alexandria P. Cogdill, Paul B. Robbins, Cancer Immunology Research	2022	120
Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors Christine N. Spencer, Vancheswaran Gopalakrishnan, Jennifer L. McQuade, Cancer Research NutritionDysbiosisHost-microbe InteractionsImmunologyPathology	2019	58
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity Isabella C. Glitza, Yongwoo David Seo, Christine N. Spencer, Cancer Discovery	2024	55

Page 1